VANI
Vivani Medical Inc.
1.20$
+0.8%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 88.1% | 93.0% | 97.5% | 94.7% | 90.9% | 90.8% | 90.1% | 79.0% | 46.6% | 45.3% | 93.0% | 50.4% | 49.2% | 45.4% | |
| 1.8% | 0.5% | 1.4% | 56.5% | 64.7% | 4.2% | 41.9% | 68.2% | 39.9% | 39.9% | 88.2% | 45.1% | 44.2% | 41.2% | |
| 55.7% | 68.4% | 80.4% | 56.5% | 64.7% | 54.1% | 41.9% | 68.2% | 39.9% | 39.9% | 88.2% | 45.1% | 44.2% | 41.2% | |
| 4.6% | 3.7% | 1.6% | 5.3% | 1.6% | 12.6% | 4.7% | 2.7% | – | – | – | – | 0.6% | 1.7% | |
| 22.4% | 18.5% | 13.3% | 29.1% | 20.3% | 18.6% | 30.4% | 6.2% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | 3.3% | 6.3% | – | – | – | – | |
| 138.1% | 172.8% | 19.6% | 28.3% | 33.7% | 45.6% | 71.1% | 56.2% | 62.6% | 54.8% | 13.3% | 54.7% | 57.6% | 60.1% | |
| 34.6% | 21.2% | 19.6% | 28.3% | 33.7% | 45.6% | 71.1% | 41.9% | 41.9% | 38.3% | 13.3% | 12.5% | 14.4% | 16.8% | |
| 0.7% | – | – | – | – | – | – | 1.4% | 26.6% | 16.7% | 1.9% | 3.0% | 3.2% | 4.6% | |
| 9.2% | 2.5% | 1.2% | 2.5% | 6.9% | 5.2% | 12.2% | 6.6% | 4.3% | 5.2% | 2.3% | 1.2% | 2.0% | 2.6% | |
| -38.1% | -72.8% | 80.4% | 71.7% | 66.3% | 54.4% | 28.9% | 43.8% | 37.4% | 45.2% | 86.7% | 45.3% | 42.4% | 39.9% | |
| -1,182.3% | -926.8% | -354.5% | -611.3% | -1,224.5% | -1,616.7% | -2,522.7% | -1,836.2% | -884.1% | -1,080.1% | -142.4% | -214.9% | -293.4% | -377.1% | |
| 59.0% | 37.2% | 7.9% | 17.3% | 32.9% | 49.0% | 80.5% | 94.1% | 538.7% | 664.8% | 74.8% | 111.0% | 132.3% | 158.4% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.